HFS
MLYS icon

Hughes Financial Services’s Mineralys Therapeutics MLYS Stock Holding History

Hughes Financial Services’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Sell
1
-1
-50% -$27 ﹤0.01% 1725
2026
Q1 		$54 Buy
+2
New +$59 ﹤0.01% 1433

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hughes Financial Services's MLYS Position: Q2 2026 in Review

Hughes Financial Services reduced its Mineralys Therapeutics (MLYS) stake by 50% in Q2 2026, selling an estimated $27 and leaving 1 share worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Hughes Financial Services first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $54 in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Hughes Financial Services held 1 share of Mineralys Therapeutics worth $27 as of Q2 2026.
  • Hughes Financial Services sold 1 Mineralys Therapeutics share in Q2 2026, an estimated $27.
  • Mineralys Therapeutics made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #1725 holding.
  • Hughes Financial Services first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Hughes Financial Services's Mineralys Therapeutics position peaked at $54 in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.